• Praxis Precision Medicines recently reported that its Phase 2/3 POWER1 trial of vormatrigine in adults with focal onset seizures did not meet the primary endpoint, although secondary measures showed a 50% responder rate, stronger seizure reduction at the higher 30 mg dose, and generally favorable tolerability.
• Despite pausing enrollment in the companion POWER2 study to reassess the program, the high proportion of patients opting into ongoing open-label treatment suggests clinicians and participants see enough clinical benefit to warrant further evaluation of vormatrigine’s role in epilepsy care.
• Against this backdrop, we’ll consider how the POWER1 miss on its primary endpoint, alongside encouraging secondary signals, reshapes Praxis’ investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Praxis Precision Medicines Investment Narrative Recap

To own Praxis today, you need to believe that its broader CNS portfolio, including ulixacaltamide and relutrigine, can offset uncertainty around vormatrigine. The POWER1 miss on the primary endpoint increases near term clinical risk for the epilepsy franchise, while the biggest catalyst now sits with upcoming regulatory decisions on relutrigine and ulixacaltamide. The company’s willingness to pause POWER2 signals that vormatrigine’s path is less straightforward, but not necessarily closed.

The most relevant recent announcement is Praxis’ June 1 release of topline POWER1 data in focal onset seizures, including the decision to pause POWER2 enrollment. This directly affects earlier expectations that the POWER1, POWER2 and POWER3 program could cleanly extend RADIANT results into pivotal settings. How Praxis adjusts its trial design and dosing strategy from here will be central to whether vormatrigine remains a key part of the near term catalyst stack.

Yet investors should also weigh the heightened risk that, if future epilepsy trials echo POWER1’s mixed outcome, Praxis may face...

Praxis Precision Medicines' narrative projects $724.1 million revenue and $89.5 million earnings by 2029. This requires 359.5% yearly revenue growth and a $362.5 million earnings increase from $-273.0 million today.

Uncover how Praxis Precision Medicines' forecasts yield a $449.13 fair value, a 81% upside to its current price.

Exploring Other Perspectives

Before this setback, the most optimistic analysts were assuming revenue of about US$2.1 billion and earnings near US$783.6 million by 2029, which is far more upbeat than consensus and now sits in clear tension with the fresh reminder that pivotal epilepsy trials can miss key endpoints and face recruitment or outcome risk.

Explore 4 other fair value estimates on Praxis Precision Medicines - why the stock might be a potential multi-bagger!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Praxis Precision Medicines research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Praxis Precision Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Praxis Precision Medicines' overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Find 46 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.